President's Cancer Panel Calls for Urgent Action to Address Gaps in Cancer Screening Uptake

WASHINGTON, Feb. 2, 2022 /PRNewswire/ -- Urgent and immediate action must be taken to ensure more effective and equitable implementation of cancer screening, according to a report released today by the President's Cancer Panel. The Panel's report, Closing Gaps in Cancer Screening: Connecting People, Communities, and Systems to Improve Equity and Access, finds that too many Americans—particularly those in communities of color and socially/economically-disadvantaged populations—are presenting with more advanced disease at the time of diagnosis, enduring aggressive treatment, or dying from cancers that could have been detected at earlier, more treatable stages. Additionally, the Panel found that many people do not receive timely, appropriate follow-up care after an abnormal result. The Panel concludes that more effective and equitable implementation of cancer screening can and will save lives and reduce the burden of cancer.

The Panel noted that at one point during the COVID-19 era, the U.S. experienced a 90-percent reduction of cancer screenings. "While screening rates were not high enough prior to 2020, during the pandemic, cancer screenings such as mammograms, colonoscopies, HPV and PAP tests, and lung cancer screenings were postponed or canceled, in many cases labeled as 'elective.' We must correct the misperception that cancer screening is 'elective,'" said John P. Williams, M.D., chair of the President's Cancer Panel. "We need to learn from the time of disruption and seize this time of opportunity because the long-term impact of missed or delayed screenings is that more people will die from cancer."

The report acknowledges there is no single barrier responsible for gaps in cancer screening uptake; some barriers are specific for a certain cancer type, while many reach across all types of cancer screening. These include lack of awareness or understanding, lack of provider recommendation, logistical challenges, fear and stigma, and concerns about cost. 

The Panel sought input from stakeholders in multiple sectors who participated in a series of working groups that informed the development of the report and the Panel's recommendations. The Panel's report outlines a multipronged approach to connect and support people, communities, and systems for cancer screening and follow-up after an abnormal result.

The Panel identified four critical goals and related recommendations to ensure the benefits of cancer screening reach all populations:

• Improve and align communication through communications campaigns and expanded National Cancer Roundtables;
• Facilitate equitable access by providing and increasing funding for community-oriented outreach and support, including robust engagement of community health workers and increasing patient access to self-sampling;
• Strengthen workforce collaborations by empowering all members of the healthcare team to support cancer screening and expand access to genetic testing; and
• Create effective health IT to make systems work better for providers and patients by creating computable guidelines and clinical decision support tools.

The complete report can be accessed at https://prescancerpanel.cancer.gov/report/cancerscreening. Hard copies may be requested via email by writing to [email protected].

The President's Cancer Panel consists of three members appointed by the President of the United States. Current members are John P. Williams, M.D., F.A.C.S., Chair, Medical Director, Breast Cancer School for Patients, and Clinical Professor, Institute for Biohealth Innovation, George Mason University; Edith P. Mitchell, M.D., M.A.C.P., F.C.P.P., F.R.C.P. (London) Clinical Professor of Medicine and Medical Oncology, Director, Center to Eliminate Health Disparities, Sidney Kimmel Cancer Care Center, Thomas Jefferson University; and Robert A. Ingram, General Partner, Hatteras Venture Partners, Former Chair, CEO Roundtable on Cancer. The Panel, established by the National Cancer Act of 1971, is an independent entity charged with monitoring the National Cancer Program and reporting to the President on any barriers to its execution. The Panel does not conduct scientific research, and while support for the Panel is provided by the National Cancer Institute (NCI) at the National Institutes of Health under the U.S. Department of Health and Human Services, its conclusions and recommendations should not be inferred as policy or perspectives of the NCI. More information about the Panel's role and background on its members can be found at https://PresCancerPanel.cancer.gov/.

CONTACT: Katherine Nicol
Direct: 202-706-7405
Cell: 410-299-7172
[email protected] 

SOURCE President's Cancer Panel